• Mundi

  Participated · Series A · Sep 2023

  Founded in 2020 and headquartered in New York with operations in Mexico, Mundi offers invoice-advancing financing to exporters so they do not have to wait 30–90 days to get paid. In addition to supply-chain financing, the company provides international payments, currency management and cargo insurance for small and medium exporters. Mundi has a track record of prior financing: a $16 million Series A led by Union Square Ventures in 2022 and a previous $100 million credit line with Silicon Valley Bank. With the new $150 million debt line from Column, Mundi's deployable portfolio capacity rises to about $325 million. The company emphasizes quick disbursement of funds and aims to provide reliable capital to Mexican exporters and their supply chains.

• Journey Clinical

  Participated · Series A · Jan 2023

  Journey Clinical provides licensed psychotherapists and eligible patients access to psychedelic-assisted psychotherapies, supplying clinicians with tools to deliver PAP and connecting patients to a medical team and network of licensed mental-health professionals. The company began with Ketamine-Assisted Psychotherapy (KAP) and plans to expand to other psychotherapeutic treatments as they are validated, researched, and approved for broader FDA use. Since opening its platform in February 2022, Journey Clinical has grown its KAP clinician network from 30 to about 700 and has treated over 1,000 patients nationwide. The company is co-founded by Jonathan Sabbagh (CEO) and Myriam Barthes (COO). Financially, Journey Clinical raised an $8.5M Series A, bringing total funding to roughly $12M. The company intends to use the funds to continue scaling its offerings across the U.S. Journey Clinical operates a decentralized clinic model that enables licensed psychotherapists to provide legal psychedelic-assisted psychotherapy, beginning with ketamine. The platform handles the pharmacology and access to prescribing clinicians while therapists deliver customized psychotherapy treatment plans. Therapists pay a $200 monthly membership for services including access to a prescriber, a white-label EHR, KAP training, a directory profile, and a peer community. Patients pay $250 for intake consultations and $150 for follow-up consultations. Journey says the market is disparate, with over a million licensed mental health professionals lacking the infrastructure and access to prescribers needed to offer these treatments. The team includes co-founder and CEO Jonathan Sabbagh, psychiatrist Kyle Lapidus MD, Ph.D., and Brigitte Gordon DNP.

No current team members are available.